PDS Biotechnology Corporation · NASDAQ:PDSB
PDS Biotechnology — Investor Presentation (January 2022)
22 slides from PDS Biotechnology's investor presentation, January 2022
Slide 1: Investor Presentation January 2022
INVESTOR PRESENTATION January 2022 Frank Bedu-Addo Ph.D. President & CEO Nasdaq: PDSB Precision Designed Science to Treat Cancer
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation (“PDSB”), and its businesses, business prospects, strategies and plans, including but not limited to statements regarding anticipated pre- clinical and clinical drug development activ
Slide 3: Corporate Overview
Corporate Overview • Clinical-stage Company developing broad-based immunotherapies to treat cancer and infectious disease • Versamune® and Infectimune™ platforms leverage the body’s own defense systems to prime antigen-specific killer T-cells and antibodies to combat cancer and infectious disease •
Slide 4: Versamune Oncology Platform
Versamune® Oncology Platform
Slide 5: Lead Asset PDS0101: HPV16-associated cancers, a $6B opportunity in the US
Lead Asset PDS0101: Designed to treat human papillomavirus (HPV16)- associated cancers, representing a $6B opportunity in the US US HPV-associated cancer incidence1, 2 Vulvar Penile • More than 40,500 patients were estimated to have been diagnosed last year with HPV16- associated cancers in the US1,
Slide 6: ASCO 2021: Triple combination shows promising durability in HPV16-positive patients
ASCO 2021: Triple combination shows promising durability of potential for anti-cancer efficacy in HPV16-positive patients PDS0101 + Bintrafusp alfa + M9241 Standard of Care (Checkpoint Inhibitors) HPV16-positive Number of checkpoint inhibitor naïve patients 6 Historical is Survival at median of 8 mo
Slide 7: ASCO 2021: Interim data suggests CD8+ killer T-cell response results in tumor shrinkage
ASCO 2021: Interim proof-of-concept data suggests targeted CD8+ killer T-cell response induced by Versamune® results in tumor shrinkage Triple Combo: PDS0101 + bintrafusp alfa + M9241 Advanced cancer patients with tumor shrinkage who had failed prior therapy HPV-16 Positive 67% (12/18) HPV-16 Negati
Slide 8: Versamune is designed to Recruit, Train and Arm T-cells in the body
Versamune® is designed to Recruit, Train and Arm T-cells in the body Versamune® + Tumor- associated proteins (antigens) 1. Recruits T-cells 2. Trains T-cells 3. Arms T-cells to lymph nodes to target tumors to kill tumor cells References: Gandhapudi SK, et al. 2019. Antigen priming with enantiospecif
Slide 9: Competitive Barrier to Entry
Competitive Barrier to Entry: Versamune® is designed to promote powerful, CD8+ killer T-cell responses in vivo Versamune®-based therapies also show promising potential to: Generate the right type and quantity of effective CD8+ killer T-cells 70-90% of cancer patients fail check point inhibitor thera
Slide 10: Strong Pipeline with Industry-Leading Partnerships
Strong Pipeline with Industry-Leading Partnerships Versamune®-based oncology pipeline is being developed in partnership with the leaders in immuno-oncology Nasdaq: PDSB Reference: Data on file. 10
Slide 11: Phase 2: PDS0101 + KEYTRUDA
Phase 2: PDS0101 + KEYTRUDA® Company-sponsored trial for the treatment of HPV16-positive metastatic/recurrent head and neck cancer (VERSATILE-002) Indication Treatment of patients with HPV16-positive head and neck cancer whose cancer has spread or returned KEYTRUDA® (Standard of Care): Anti-PD1 chec
Slide 12: Phase 2: PDS0101 + Chemoradiotherapy
Phase 2: PDS0101 + Chemoradiotherapy Investigator-led trial evaluating the combination in patients with locally advanced cervical cancer (IMMUNOCERV) Indication Treatment of patients with locally advanced cervical cancer – Stages IB3-IVA Clinical Chemoradiotherapy (CRT – Standard of Care): Cisplatin
Slide 13: PDS0102: TARP Antigen
PDS0102: TARP Antigen Greater quantity and quality of Versamune®-induced CD8+ killer T-cells may result in ability to treat TARP positive prostate and breast cancers PRE-CLINICAL OPTIMIZATION STUDIES1: TARP-Specific T-cell Induction after 2 injections of PDS0102 TARP Total $40B Market Opportunity* A
Slide 14: PDS0103: MUC1 Antigen
PDS0103: MUC1 Antigen Greater quantity and quality of Versamune®-induced CD8+ killer T-cells may result in ability to treat MUC1-positive cancers 500 # of Antigen-Recognizing CD8+ T-Cells $100B MUC1 Total 450 IFN-γ Spot Forming Cells/1X106 Spleen Cells 400 Market 350 Opportunity* 300 250 Induced a >
Slide 15: Infectimune Infectious Disease Platform
Infectimune™ Infectious Disease Platform
Slide 16: PDS Biotech's Infectimune Pipeline
PDS Biotech’s Infectimune™ Pipeline Developed in partnership with leaders in infectious disease *Consortium of PDS Biotech, Farmacore Biotechnology and Blanver Farmoquimica. Funding provided by The Ministry of Science, Technology and Innovation of Brazil (“MCTI”). Nasdaq: PDSB Reference: Data on fil
Slide 17: Infectimune Pipeline
Infectimune™ Pipeline Update on infectious disease Universal Flu • Announced Option Agreement for license with University of Georgia for universal flu antigens • Preclinical work complete COVID • Agreement with Farmacore extended through May 2022 • Scale up and manufacturing currently in process Nas
Slide 18: Near-Term Milestones
Near-Term Milestones
Slide 19: Projected milestones through 2022
Projected milestones through 2022* PDS Biotech Funded Clinical Trials Partner Co-Funded Clinical Trials 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 Preliminary efficacy data from advanced HPV-associated cancer trial (NCI) Interim data from HPV-associated cancer trial (NCI) PDS0101 Expected completion of HPV-
Slide 20: PDS Biotech Management
PDS Biotech Management Historical success in the development and commercialization of leading pharmaceutical products • Senior executive experience with management of strategy and execution at both large pharma and biotechs Frank Bedu-Addo, PhD • Notable drug development: Chief Executive Officer ® A
Slide 21: Corporate Overview
Corporate Overview • Clinical-stage Company developing broad-based immunotherapies to treat cancer and infectious disease • Versamune® and Infectimune™ platforms leverage the body’s own defense systems to prime antigen-specific killer T-cells and antibodies to combat cancer and infectious disease •
Slide 22: Precision Designed Science to Treat Cancer
Nasdaq: PDSB Precision Designed Science to Treat Cancer
PDS Biotechnology — Investor Presentation (January 2022) on 6ix